ValuEngine lowered shares of Stemline Therapeutics (NASDAQ:STML) from a hold rating to a sell rating in a research note released on Wednesday morning.
STML has been the topic of several other research reports. BidaskClub lowered Stemline Therapeutics from a hold rating to a sell rating in a research note on Friday, December 22nd. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the company a buy rating in a research note on Thursday, December 14th. Finally, Zacks Investment Research upgraded Stemline Therapeutics from a sell rating to a hold rating in a research report on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $33.75.
Shares of Stemline Therapeutics (NASDAQ STML) traded up $0.90 on Wednesday, hitting $18.50. The stock had a trading volume of 284,746 shares, compared to its average volume of 216,244. Stemline Therapeutics has a one year low of $7.30 and a one year high of $18.50.
Hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC bought a new stake in Stemline Therapeutics during the 2nd quarter worth $102,000. Royce & Associates LP acquired a new position in Stemline Therapeutics during the 4th quarter worth about $106,000. Nationwide Fund Advisors lifted its holdings in Stemline Therapeutics by 7.2% during the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 855 shares during the period. Two Sigma Investments LP acquired a new position in Stemline Therapeutics during the 4th quarter worth about $170,000. Finally, Alliancebernstein L.P. acquired a new position in Stemline Therapeutics during the 2nd quarter worth about $178,000. Institutional investors and hedge funds own 50.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Stemline Therapeutics (STML) Downgraded by ValuEngine” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2018/03/11/stemline-therapeutics-stml-downgraded-by-valuengine.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.